**Core tip:** This case report describes a patient who was clinically diagnosed as advanced gastric cancer, but final pathological confirm diagnosis was to be breast cancer with gastric metastasis. Patient received systemic chemotherapy and is currently on partial response state at present.

INTRODUCTION
============

Breast cancer commonly metastasizes to bone, lung, liver, and brain, but metastasis to the gastrointestinal tract is rare\[[@B1],[@B2]\]. In Korea, fewer than 10 cases of breast cancer metastasizing to the gastrointestinal tract have been reported\[[@B3]\]. Breast cancer with gastrointestinal metastasis requires systemic chemotherapy. However, if breast cancer with gastrointestinal metastasis is misdiagnosed as a primary gastrointestinal cancer, unnecessary surgical resection may take over place. Herein, the authors present a case of breast cancer metastasizing to the stomach, initially suspected to be primary gastric cancer. This patient was successfully treated with systemic chemotherapy.

CASE REPORT
===========

A 65-year-old female patient was referred to the oncology department for evaluation of indigestion and epigastric discomfort. She had been previously diagnosed with breast cancer, treated with modified radical mastectomy (invasive lobular carcinoma, pT2N3M0), adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-FU) and adjuvant radiation. Two years after surgery, she experienced cancer recurrence with bone metastasis and received an aromatase inhibitor (letrozole) as treatment for another 2 years. At the time she visited the oncology department, she was currently on aromatase inhibitor (letrozole). Other than breast cancer, she had no other medical history. Her last endoscopy was performed 2 years ago, with no specific findings.

Initial white blood cell (WBC) counts, hemoglobin level and hematocrit were 4790 cell/mm^3^ (neutrophil count 82%, lymphocytes count 25.8%), 13.1 g/dL (normal range 13.0-18.0 g/dL), and 369000/mm^3^ (normal range 150000-450000/mm^3^). Other laboratory findings including those of blood chemistry and urine analysis were in the normal range. Serum carcinoembryonic antigen level was increased up to 23.25 ng/dL.

Endoscopy revealed diffuse infiltration with nodular mucosal thickening of the stomach wall, involving the lower two-thirds of the stomach body (Figure [1](#F1){ref-type="fig"}). Based on endoscopy, endoscopic ultrasound (Figure [2A](#F2){ref-type="fig"}) and abdominal CT scan (Figure [2B](#F2){ref-type="fig"}), advanced gastric cancer (cT3N1M0) was suspected. Hematoxylin and eosin (H&E) staining of the endoscopic biopsy revealed poorly cohesive tumor cells spreading into the gastric mucosa, suggesting signet ring cell carcinoma. However, no intracytoplasmic mucin was found in the tumor cells, with scant to moderate pinkish cytoplasm. Normal stomach glandular tissue was found in the biopsy specimen, with no cancer cells connected to the glandular structure (Figure [3A](#F3){ref-type="fig"} and B). These findings were not consistent with typical gastric signet ring cell carcinoma. Because the patient was diagnosed with invasive lobular carcinoma, archival breast tumor tissue was re-evaluated for comparison.

![Upper endoscopy shows diffuse infiltrative mucosal lesion with extensive nodular thickening of the stomach wall, involving lower two-thirds of body.](WJG-23-2251-g001){#F1}

![Endoscopic ultrasound shows subserosal invasion of the gastric lesion with lymph node involvement (A, B). Abdomen CT scan shows infiltrative gastric lesion involving cardia and angle of stomach (arrowhead) with enlarged perigastric lymph node (arrow).](WJG-23-2251-g002){#F2}

![Pathologic features of endoscopic biopsy specimen. Discohesive tumor cells are infiltrated in the stroma of the stomach mucosal tissue (HE × 40, A). Tumor cells show enlarged centrally located nucleus without intracytoplasmic clear mucin. The tumor cells had no connection to the remained normal gastric mucosal tissue (HE × 400, B). Previous breast cancer pathology was reviewed (C). Discohesive tumor cells were arranged in indian file. The tumor cells had enlarged centrally located nucleus without intracytoplasmic mucin (HE × 400, C). Immunohistochemical stains and molecular test of tumor was done (D-J). Diffuse strong nucleus expression of GATA3 was observed (GATA3 × 400, D). Focal, less than one percentage cytoplasmic expression of GCDFP was detected (GCDFP × 400, E). Negative stain for E-cadherin (E-cadherin × 400, F). Negative stains for ER and PR (ER × 400, PR × 400, G, H). Immunohistochemical stain for HER-2 was equivocal (HER-2 × 400, I). Silver in situ hybridization (SISH) for determination of HER2 gene status. Occasional HER2 gene amplified cells were noted in the mixture with normal HE2 gene expressing cells (SISH × 1000, J).](WJG-23-2251-g003){#F3}

Breast tissue pathology showed a similar appearance to the endoscopic biopsy specimen, such as a de-cohesive pattern with cells arranged in an Indian file pattern, and a centrally located enlarged nucleus (Figure [3C](#F3){ref-type="fig"}). In the immunohistochemical (IHC) test, the tumor cells showed diffuse strong nuclear staining for GATA3 binding protein (GATA3) (Figure [3D](#F3){ref-type="fig"}). IHC results of gross cystic disease fluid protein-15 (GCDFP-15) (Figure [3E](#F3){ref-type="fig"}), E-cadherin (Figure [3F](#F3){ref-type="fig"}), estrogen receptor (ER, Figure [3G](#F3){ref-type="fig"}) and progesterone receptor (PR, Figure [3H](#F3){ref-type="fig"}) were negative. HER-2 IHC staining showed weak membranous staining consistent with equivocal (+2) positivity (Figure [3I](#F3){ref-type="fig"}). Silver in situ hybridization (SISH) for HER-2 gene was performed, and the dual-probe HER2/Chr17 ratio was 3.2 (161/51), consistent with HER-2 amplification (Figure [3J](#F3){ref-type="fig"}).

Based on the pathologic findings, breast cancer metastasizing to the stomach was diagnosed. The stomach metastasis developed 4 years after surgery and 2 years after the initiation of an aromatase inhibitor use. As systemic treatment, docetaxel combined with trastuzumab was considered but trastuzumab was not available due to insurance guidelines. Docetaxel (75 mg/m^2^ intravenously \[I.V.\], day 1) was administered every 3 wk. After 2 cycles of systemic chemotherapy, follow up abdominal CT scans showed decreased stomach wall thickness, and perigastric lymph nodes showed a partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (Figure [4](#F4){ref-type="fig"}). During 2 cycles of systemic chemotherapy, the patient's symptoms of indigestion and epigastric discomfort regressed. Currently, the patient is in persistent PR state and 6 cycles of docetaxel have been administered.

![Response evaluation after 2 cycles of docetaxel chemotherapy (A, B). Abdominal CT scan shows decreased perigastric lymph modes (arrows) and gastric mucosal thickening (arrowheads).](WJG-23-2251-g004){#F4}

DISCUSSION
==========

Cancer metastasizing to the gastrointestinal (GI) tract is reported to be rare, but breast cancer is the second most common cancer metastasizing to the GI tract after lung cancer\[[@B2],[@B4]\]. However, the incidence of breast cancer with GI tract metastasis is reported to be 1% or lower\[[@B5],[@B6]\]. Invasive lobular carcinoma tends to metastasize to the GI tract more frequently compared to invasive ductal carcinoma\[[@B7]\]. The most common metastatic sites in the GI tract are the colon and rectum, stomach, small intestine and esophagus, in that order\[[@B4]\]. In Korea, 7 cases of breast cancers metastasizing to the GI tract have been reported, with 5 cases of breast cancer with gastric metastases and 2 cases of synchronous stomach and colorectal metastases\[[@B3]\]. The clinical characteristics of the previous cited cases are summarized in Table [1](#T1){ref-type="table"}\[[@B2],[@B3],[@B8]-[@B19]\].

###### 

Clinical characteristics of representative gastric metastasis of breast cancer

  **Ref**.                   **Age**                        **Duration after initial diagnosis**   **Clinical presentation**     **Endoscopy**                         **Pathology**   **IHC**   **Surgery**   **Treatment**   **Other metastases site**      **Overall survival**                                                  
  -------------------------- ------------------------------ -------------------------------------- ----------------------------- ------------------------------------- --------------- --------- ------------- --------------- ------------------------------ ------------------------- ------------------------------------------- -----
  Our case                   65                             4                                      Epigastric Discomfort         Diffuse infiltrative mucosal lesion   ILC             neg       neg           pos             No                                                       Bone                                        \-
  Indigestion                Extensive nodular thickening                                                                                                                                                                                                                                                                           
  Pera et al\[[@B18]\]       45                             7                                      Epigastric pain               Erosion of gastric wall               ILC             pos       pos           \-              Subtotal gastrectomy           H                         \-                                          \-
  heart burn                                                                                                                                                                                                                                                                                                                        
  Jones et al\[[@B2]\]       51                             3                                      No symptom                    Polyp at antrum wall                  ILC             neg       neg           neg             Total gastrectomy              Palliative                Bone                                        \-
  61                         6.9                            Dysphagia                              Fungating mass                ILC                                   pos             pos       neg           No              C,R                            Brain, bone, pleura       \-                                          
  weight loss                                                                                                                                                                                                                                                                                                                       
  Eo et al\[[@B11]\]         48                             9                                      Nausea                        Elevated mucosal lesion               IDC             pos       pos           neg             No                             C                         Liver, bone, pleura                         \-
  anorexia                                                                                                                                                                                                                                                                                                                          
  Arrangoiz et al\[[@B8]\]   70                             1                                      Diarrhea                      Mucosal thickening                    ILC             pos       neg           neg             No                             H                         Lung, rectum                                \-
  constipation                                                                                                                                                                                                                                                                                                                      
  Koike et al\[[@B16]\]      42                             5                                      Epigastric pain               Mucosal erosion                       ILC             pos       pos           neg             No                             C                         \-                                          \-
  54                         6                              Epigastric pain                        Mucosal erosion               ILC                                   pos             pos       neg           No              C, H                           Liver, bone, peritoneum   5                                           
  54                         3                              Epigastric pain                        Submucosal tumor              IDC                                   pos             pos       pos           No              C                              Bone                      2.3                                         
  vomiting                                                                                                                                                                                                                                                                                                                          
  Geredeli et al\[[@B12]\]   47                             3                                      Increased serum CEA, CA15-3                                         ILC             neg       neg           neg             Subtotal gastrectomy           C                         Bone                                        \-
  Buka et al\[[@B9]\]        58                             1.2                                    Abdominal pain                Polypoid infiltration                 ILC             pos       pos           neg             Total gastrectomy              C, R                      Colon, pleura                               7.2
  weight loss                                                                                                                                                                                                                                                                                                                       
  Lee et al\[[@B17]\]        48                             5.7                                    Melena                        Mucosal erosion                       \-              \-        \-            \-              \-                             C                         Bone, liver                                 \-
  Yim et al\[[@B19]\]        48                             Initial diagnosis                      Epigastric discomfort         Mucosal erosion                       ILC             neg       neg           \-              No                             C                         Bone                                        \-
  Jeon et al\[[@B14]\]       49                             5                                      Melena                        Volcano shaped ulcers                 IDC             pos       neg           \-              No                             C                         Bone                                        
  Kim et al\[[@B15]\]        53                             10                                     Dyspepsia                     Mucosal erosion                       IDC             neg       neg           \-              No                             C, H                      Kidney, ovary, colon, bone, peritoneal LN   2.4
  lower abdominal pain                                                                                                                                                                                                                                                                                                              
  small caliper of stool                                                                                                                                                                                                                                                                                                            
  Hwang et al\[[@B13]\]      66                             17                                     Back pain                     Flat mucosal lesion                   ILC             neg       pos                           endoscopic mucosal resection   C                         Bone                                        \-
  Cheoi et al\[[@B10]\]      56                             4                                      Upper abdominal discomfort    Mucosal erosion                       IDC             neg       pos           pos             \-                             C, H                      \-                                          1.3
  Yu et al\[[@B3]\]          63                             10                                     Melena                        Linitis plastica                      ILC             pos       pos           pos             No                             C, H                      Colon, bone marrow                          \-
  small caliper of stool     flat ulcer                                                                                                                                                                                                                                                                                             

ILC: Invasive lobular carcinoma; IDC: Invasive ductal carcinoma; IHC: Immunohistochemical stain; pos: Positive; neg: Negative; C: Chemotherapy; H: Hormonal treatment.

Most breast cancer patients with gastric metastasis present with GI symptoms\[[@B3],[@B16]\], similar to primary gastric cancer. In our case, the patient complained of indigestion, early satiety, and weight loss. Endoscopy with sufficient mucosal biopsy is mandatory for the diagnosis. Diffuse infiltration of the gastric wall with linitis plastica formation may be found\[[@B2]\], but approximately 50% of patients may have shallow mucosal lesion indistinguishable from benign gastric mucosal lesions\[[@B20]\]. Our patient showed extensive nodular mucosal thickening with a thickened gastric fold, with a primary suspicion of advanced gastric cancer.

Pathologic findings of breast cancer metastasizing to the stomach are morphologically similar to poorly cohesive gastric carcinoma, especially in invasive lobular carcinoma\[[@B21],[@B22]\]. However, some morphological differences are present. In metastatic mammary carcinoma, sialomucin is present in the intracytoplasmic lumina with a central location of the nucleus. In contrast, primary gastric signet ring cell carcinoma contains clear intracytoplasmic acid mucin that pushes the nucleus to the periphery\[[@B21]\]. In the present case, the nuclei of the tumor cells were located in the center, and there were no clear intracytoplasmic inclusions.

Also, IHC study is helpful for differential diagnosis. GCDFP-15 staining was traditionally used for differential diagnosis of mammary origin carcinoma. However, it shows relatively low sensitivity (55%-76%) for detecting a breast origin cancer\[[@B23]\]. Recently, GATA3 is widely known as a mammary cancer and urothelial cancer marker. GATA3 expression shows 100% positivity in involving breast lobular carcinoma and 96% positivity in breast ductal carcinoma. However, only 5% of tumors are positive for GATA3 in gastric adenocarcinoma\[[@B24]\]. In our case, although GCDFP-15 staining was negative, GATA3 showed diffuse strong nuclear positivity, consistent with a mammary origin of the carcinoma.

Metastatic breast cancer involving the stomach is treated with systemic agents such as cytotoxic chemotherapeutic agents or hormonal agents. Surgical resection of the stomach has a limited role in treatment, and does not affect the survival outcomes of patients presenting with gastric metastasis\[[@B4]\]. However, surgical treatment may have a role in palliative treatment such as relieving obstructive symptoms.

Breast cancer patients have a superior survival outcome compared to other cancers, raising the possibility of a double primary cancer during the clinical course. However, metastasis of primary breast cancer must also be considered. In a breast cancer patient who complains of gastrointestinal symptoms, prompt endoscopy and biopsy are necessary for an accurate diagnosis. Sufficient pathologic review of gastric biopsy and previous breast specimens, with immunohistochemical examination is warranted. When metastasis of breast cancer to the stomach is suspected, appropriate systemic treatment is necessary for further treatment.

COMMENTS
========

Case characteristics
--------------------

A 65-year-old female patient who was diagnosed as metastatic breast cancer visited the hospital for evaluation of epigastric discomfort.

Clinical diagnosis
------------------

Epigastric discomfort and indigestion.

Differential diagnosis
----------------------

Gastric ulcer, primary gastric cancer showed be differentiated by endoscopic biopsy.

Laboratory diagnosis
--------------------

Serum carcinoembryonic antigen was increased up to 23.25 ng/dL.

Imaging diagnosis
-----------------

Endoscopy showed diffuse infiltration with nodular mucosal thickening of stomach wall.

Pathological diagnosis
----------------------

Metastatic invasive lobular carcinoma to stomach was diagnosed by immunohistochemical stain.

Treatment
---------

Docetaxel 150 mg/m^2^ intravenous, every 3 wk.

Related reports
---------------

Breast cancer rarely metastasize to gastrointestinal tract and should be diagnosed by careful review of the pathologic specimen. If patient have underlying breast cancer, metastatic breast cancer should be considered other than primary gastric cancer during the diagnosis.

Term explanation
----------------

GATA3 refers to GATA3 binding protein used for differential marker for diagnosis of breast cancer. Partial response (PR) means more than 30% decrease in the sum of the longest diameters of target lesions during response evaluation.

Experiences and lessons
-----------------------

Early differential diagnosis of metastatic breast cancer to stomach is important for appropriate systemic chemotherapy and avoidance of unnecessary surgery.

Peer-review
-----------
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